Nicotinamide Riboside for Parkinson's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether Nicotinamide Riboside (NR), a form of Vitamin B3, can improve blood vessel health in the brain, boost memory, and enhance physical function. Researchers compare NR to a placebo (an inactive substance) to determine any benefits. The trial includes participants with Parkinson's disease who can walk and complete seated tasks. Over 13 weeks, participants will attend three study visits at the University of Oklahoma, undergoing memory tests, blood vessel checks, and physical function assessments.
As an unphased trial, this study allows participants to contribute to groundbreaking research that could lead to new insights and treatments for Parkinson's disease.
Is there any evidence suggesting that Nicotinamide Riboside is likely to be safe for humans?
Research has shown that nicotinamide riboside (NR) is generally safe for people. One study found that participants who took 3000 mg of NR daily for 30 days tolerated it well, with no serious safety concerns. Another study with a daily dose of 1000 mg also reported good tolerance. There were no reports of moderate or severe side effects, and mild side effects were similar to those in the group not taking NR. These findings suggest that NR can be safely taken at these doses, making it a promising option for further research in conditions like Parkinson's disease.12345
Why are researchers excited about this trial?
Researchers are excited about nicotinamide riboside (NR) for Parkinson's disease because it introduces a novel approach to treatment by focusing on cellular energy production. Unlike standard treatments that primarily aim to manage symptoms through dopamine replacement, NR works by boosting levels of NAD+, a molecule crucial for cell metabolism and energy. This unique mechanism could potentially protect neurons from degeneration, offering a new way to tackle the disease's progression rather than just addressing its symptoms.
What evidence suggests that Nicotinamide Riboside might be an effective treatment for Parkinson's Disease?
This trial will compare the effects of Nicotinamide Riboside (NR) with a placebo in participants with Parkinson's disease. Studies have shown that NR, a type of Vitamin B3, might benefit people with Parkinson's disease. Research suggests that NR can boost energy levels in the brain and reduce inflammation, both crucial for brain health. Some studies found that taking NR improved movement problems in people with Parkinson's. Additionally, NR has been linked to an increase in NAD, a molecule that supports energy production and cell repair in the brain. However, effects can vary among individuals, and more research is needed to fully understand its benefits.12345
Who Is on the Research Team?
Andriy Yabluchanskiy, MD, PhD
Principal Investigator
University of Oklahoma Health Campus
Are You a Good Fit for This Trial?
This trial is for people diagnosed with Parkinson's disease who are able to attend three study visits over about 13 weeks. Specific inclusion and exclusion criteria are not listed, but participants must be eligible based on the study team's assessment.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline
Baseline assessments including questionnaires, memory testing, non-invasive blood vessel measurements, physical function tests, and a blood draw
Treatment
Participants receive either nicotinamide riboside or placebo daily for 12 weeks
Follow-up
Participants are monitored for changes in neurovascular coupling, cognitive performance, physical function, and other health metrics
What Are the Treatments Tested in This Trial?
Interventions
- Nicotinamide Riboside (NR)
Trial Overview
The study tests whether Nicotinamide Riboside (NR), a form of Vitamin B3, can improve brain blood vessel health, memory, and physical function in people with Parkinson's. Participants get either NR or a placebo by random assignment.
How Is the Trial Designed?
2
Treatment groups
Active Control
Placebo Group
Participants will be randomized to receive either oral nicotinamide riboside at a total daily dose of 1 g or an identically appearing placebo for 12 weeks.
Participants assigned to the placebo arm will take an oral placebo capsule daily for 12 weeks. The placebo will appear identical to the nicotinamide riboside capsules.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Oklahoma
Lead Sponsor
Presbyterian Health Foundation
Collaborator
Citations
NR-SAFE: a randomized, double-blind safety trial of high dose ...
Oral nicotinamide riboside (NR) at a dose of 3000 mg daily for 30 days is safe and associated with a pronounced systemic augmentation of the NAD metabolome, but ...
NCT05589766 | N-DOSE: A Dose Optimization Trial of ...
The NADPARK study showed that NR 1000mg daily was well tolerated and led to a significant, but variable, increase in cerebral NAD (nicotinamide adenine ...
The NADPARK study: A randomized phase I trial of ...
NAD increase is associated with clinical improvement in Parkinson's disease • NR induces transcription of mitochondrial, lysosomal, and ...
Nicotinamide riboside first alleviates symptoms but later ...
Our results suggest that reduction in 26/20S function with long term NR treatment may increase risk for developing reduced nigrostriatal DA function.
5.
parkinsonsnewstoday.com
parkinsonsnewstoday.com/news/nicotinamide-riboside-supplement-shows-promise-parkinsons-trial/Nicotinamide riboside supplement shows promise for ...
In a small Parkinson's clinical trial, one month of a high-dose nicotinamide riboside supplement was seen to ease patients' motor symptoms.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.